Based on recent data from pre-clinical studies and preliminary clinical trials with MSC+ stem cells and its effects on IPF, indicate that over 84% of patients with diffuse parenchymal lung disease showed improvements in their overall quality of life after copd stem cell therapy. While it's not a cure for chronic lung disease, lung stem cell therapy can help patients manage IPF and interstitial lung disease symptoms more effectively.